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Abstract
Introduction: Lesional skin of patients with discoid lupus erythematosus (DLE) contains macrophages, whose
polarization has yet to be investigated. To test our hypothesis that M1 macrophages would be increased in DLE
skin, we examined transcriptome alterations in immune cell gene expression and macrophage features in DLE and
normal skin by using gene expression and histochemical approaches.
Methods: Gene expression of RNA from DLE lesional and normal control skin was compared by microarrays and
quantitative real-time polymerase chain reaction (RT-PCR). Both skin groups were analyzed for CD163 expression by
immunohistochemistry. Double immunofluorescence studies were performed to characterize protein expression of
CD163+ macrophages.
Results: DLE skin had twice as many upregulated genes than downregulated genes compared with normal skin.
Gene set enrichment analysis comparing differentially expressed genes in DLE and normal skin with previously
published gene sets associated with M1 and M2 macrophages showed strong overlap between upregulated genes
in DLE skin and M1 macrophages. Quantitative RT-PCR showed that several M1 macrophage-associated genes—e.g.,
chemokine (C-X-C motif) ligand 10 (CXCL10), chemokine (C-C motif) ligand 5 (CCL5), and signal transducer and
activator of transcription 1 (STAT1)—had amplified mRNA levels in DLE skin. CD163+ macrophages were increased near
the epidermal-dermal junction and perivascular areas in DLE skin compared with normal skin. However, double
immunofluorescence studies of CD163+ macrophages revealed minor co-expression of M1 (CXCL10, tumor
necrosis factor-alpha, and CD127) and M2 (CD209 and transforming growth factor-beta) macrophage-related
proteins in DLE skin.
Conclusion: Whereas a subset of CD163+ macrophages displays mixed polarizations in DLE skin, other immune
cells such as T cells can contribute to the expression of these macrophage-related genes.
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Introduction
Discoid lupus erythematosus (DLE), the most common
chronic cutaneous lupus subtype [1, 2], is a photosensi-
tive and disfiguring skin disease marked by erythematous
scaly papules that transition into hyper- and hypopig-
mented scarring plaques located most commonly on the
face, scalp, and neck [3, 4]. Ten to twenty percent of pa-
tients with systemic lupus erythematosus (SLE) have di-
agnosed DLE [5–7], whereas up to 17 % of patients
presenting with an initial diagnosis of DLE develop SLE
[1, 8, 9]. Moreover, in light of this overlap, recent studies
have shown that multiple gene variations are shared by
patients with SLE and patients with DLE [10, 11].
Much attention has been directed toward understand-
ing how T and B cells are involved in cutaneous lupus.
Although macrophages are the second most common
inflammatory cells in DLE skin (next to T cells) [12–14],
they are a relatively understudied population in DLE.
Macrophages can direct T-cell differentiation and facili-
tate antigen presentation, thus influencing immune re-
sponses in DLE. Macrophages can be differentially
activated into M1 and M2 subtypes, which have
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contrasting functions. M1 macrophages (classically acti-
vated macrophages) assume the traditional roles of
phagocytes, which include targeting and clearing mi-
crobes, and depict type I immune responses. They pro-
duce pro-inflammatory reactive oxygen species and
cytokines such as interleukin-12 (IL-12). M2 macro-
phages (alternatively activated macrophages) counteract
type I immune responses with the induction of type II
immune responses via secretion of IL-10, resulting in
resolution of inflammation. Blood in patients with SLE
demonstrated upregulation of M1 macrophage proteins
such as chemokine (C-X-C motif ) ligand 10 (CXCL10)
[15] and downregulation of M2 macrophage proteins,
including transforming growth factor-beta (TGF-β) [16].
However, whether this bias carries over into target tis-
sues of patients with lupus, such as skin, is unknown.
Our objective in this study was to investigate changes
in immune cell signatures in the transcriptomes of DLE
lesional skin versus normal skin by microarray analysis
and quantitative real-time polymerase chain reaction
(qRT-PCR). Protein expression was assessed by immu-
nohistochemistry and double immunofluorescence. Be-
cause lesional skin from patients with inflammatory skin
diseases such as psoriasis [17] has been characterized by
a distinctly greater presence of classically activated mac-
rophages, we hypothesized that, compared with normal
skin, DLE lesional skin would also exhibit a strong M1
macrophage polarization.
Methods
Patient recruitment and sample/data collection
Subjects with DLE, diagnosed by clinicopathological cor-
relation, were recruited from the outpatient dermatology
clinics at Parkland Health and Hospital System and
University of Texas Southwestern (UTSW) Medical
Center. Normal controls were additionally recruited
from elective plastic surgery cases performed at UTSW
Medical Center. DLE patients having individual lesions
with a Cutaneous Lupus Activity and Severity Index
(CLASI) activity score of at least 2 were included. DLE
patients who had SLE, based on fulfillment of at least
four American College of Rheumatology (ACR) diagnos-
tic criteria [18] or a history of drug-induced DLE, and
normal subjects with a personal history of autoimmune
disease were excluded. On the basis of these screening
criteria, 17 patients with DLE and 12 normal controls
gave informed consent and were enrolled in the study.
Medical, family, and medication histories were obtained,
and clinical assessments (e.g., CLASI and Systemic
Lupus Erythematosus Disease Activity Index, or SLEDAI)
performed at the study visit were collected. Patient charac-
teristics are summarized in Table 1, which is subdivided
by disease group (normal and DLE) and experiments
(microarray and qRT-PCR). DLE subjects underwent one
4- or 6-mm punch biopsy from active inflammatory bor-
ders of discoid lesions with individual CLASI activity
scores of at least 2. Normal sun-exposed non-lesional skin
was obtained as discarded specimens from cutaneous sur-
geries or elective plastic surgeries. Skin biopsies were
placed in RNALater Solution (Ambion, Austin, TX, USA),
kept at room temperature overnight, and stored at −80 °C
for RNA analysis or in OCT and frozen in −80 °C for im-
munofluorescence experiments. This study was approved
by the University of Texas Southwestern Institutional
Review Board and complied with Declaration of Helsinki.
Microarray analysis
RNA from nine DLE lesional and eight normal skin sec-
tions was extracted by using RNeasy Lipid Tissue Mini
kit (Qiagen, Hilden, Germany). RNA quality was evalu-
ated with an Agilent Bioanalyzer (Agilent Technologies,
Santa Clara, CA, USA) and quantified by spectropho-
tometry. Biotinylated RNA was amplified by using the
TotalPrep RNA amplification kit (Ambion) and hybrid-
ized with Illumina Sentrix Expression Beadchips, Human
HT-12v4 (Illumina, San Diego, CA, USA). Each array
contains more than 31,000 probed genes. Microarray
data have been submitted to the public repository, Gene
Expression Omnibus.
Reverse transcription and qRT-PCR
Skin RNA from 17 patients with DLE and 12 normal
controls was reverse-transcribed into cDNA by using the
iScript cDNA Synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA). cDNA of selected genes using for-
ward and reverse primers (Additional file 1: Table S1) was
amplified with SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) in accordance with the
instructions of the manufacturer. qRT-PCR under the fol-
lowing conditions (3 minutes at 95 °C, then 40 cycles of
20 seconds at 95 °C, 1 minute at 55 °C, and 30 seconds at
72 °C) was performed in a CFX96 qRT-PCR machine
(Bio-Rad Laboratories). Cycle threshold (CT) values were
standardized to the housekeeping gene GAPDH (glyceral-
dehyde-3-phosphate dehydrogenase) and converted to fold
change by using the 2−ΔΔCT formula [19].
Immunohistochemistry analysis
A subset of DLE lesional (n = 5) and normal skin (n = 6)
biopsies were bisected and transferred in 10 % formalin.
Four-micron sections were deparaffinized in xylene and
rehydrated in graded alcohols to distilled water. En-
dogenous peroxidase activity was quenched for 10 mi-
nutes at room temperature by using 0.3 % H2O2 and
0.1 % sodium azide. For epitope retrieval, slides were
placed in 1 mM EDTA, pH 8.5, for 30 minutes in a
steamer and then cooled for 10 minutes. Slides were
incubated with mouse monoclonal anti-CD163
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antibody (Neomarkers/Thermo Fisher Scientific,
Waltham, MA, USA) or isotype control for 50 minutes
at 25 °C [20]. After phosphate-buffered saline (PBS)
rinse, horseradish peroxidase-conjugated goat anti-
rabbit horseradish peroxidase-conjugated IgG anti-
body (Leica Novocastra, Wetzlar, Germany) [21] was
added for 45 minutes at 25 °C [20]. Finally, the slides
were immersed for 8 minutes in 25 °C diaminobenzi-
dine (Invitrogen, Carlsbad, CA, USA), enhanced with
0.5 % copper sulfate in PBS for 1–3 minutes at 25 °C,
counterstained in hematoxylin, and dehydrated in
graded alcohols and xylene. Cell counts were per-
formed by two independent evaluators (BC and GH)
on the most representative sections in the epidermal-
dermal junction, perifollicular, and perivascular areas
of the biopsies by using ImageJ [22]. Cell counts were
averaged and divided by surface area assessed.
Immunofluorescence
Six-micron frozen DLE (n = 6–8) and normal (n = 4–5)
skin sections fixed in acetone were blocked in 5 % nor-
mal goat serum in PBS with 0.3 % Triton X-100 for 1
hour. Slides were then incubated with rabbit anti-human
primary antibodies—CD127 (Abcam, Cambridge, MA,
USA), CD209 (Abcam), CXCL10 (PeproTech, Rocky
Hill, NJ, USA), tumor necrosis factor-α (TNF-α) (Novus,
Littleton, CO, USA), and TGF-β (Novus)—overnight
followed by PBS washes. Alexa Fluor® 488-conjugated
goat anti-rabbit antibodies (Life Technologies, Carlsbad,
CA, USA) were added for 30 minutes followed by PBS
washes, except for TGF-β and TNF-α antibody-stained
slides, whose signals were amplified by using the TSA
Biotin kit in accordance with the instructions of the
manufacturer (PerkinElmer, Waltham, MA, USA).
Mouse anti-human CD163 antibody (Novus) or mouse
Table 1 Subject demographic data
Normal (microarray) DLE (microarray) Normal (qRT-PCR) DLE (qRT-PCR)
Number 8 9 12 17
Age at visit in years, median (range) 47.0 (40.9–54.0) 40.0 (21.5–56.5) 48.0 (39.3–66.4) 40.2 (21.5–59.9)
Gender, male/female 1/7 1/8 3/9 4/13
Ethnicity, N (%)
African-American 0 (0) 7 (77.8) 0 (0) 12 (70.6)
Caucasian 8 (100) 0 (0) 12 (100) 4 (23.5)
Hispanic 0 (0) 2 (22.2) 0 (0) 1 (11.1)
CLASI activity score, median (range) N/A 6 (2–20) N/A 7 (2–21)
CLASI damage score, median (range) N/A 14 (6–20) N/A 10 (0–20)
SLEDAI score, median (range) N/A 0 (0–0) N/A 0 (0–4)
Disease duration in years, median (range)a N/A 2.8 (0–16.3) N/A 1.5 (0–16.3)
Lupus medications, N (%)
Topical/intralesional corticosteroids/topical immunomodulators N/A 5 (55.6) N/A 12 (70.6)
Hydroxychloroquine N/A 4 (44.4) N/A 8 (47.0)
Quinacrine N/A 0 (0) N/A 1 (5.9)
Methotrexate N/A 0 (0) N/A 1 (5.9)
None N/A 2 (22.2) N/A 4 (23.5)
ACR SLE criteria, N (%)b
Discoid rash N/A 9 (100) N/A 17 (100)
Photosensitivity N/A 7 (77.8) N/A 12 (70.6)
Oral ulcers N/A 2 (22.2) N/A 3 (17.6)
Hematological disorder N/A 1 (11.1) N/A 1 (11.1)
Anti-nuclear antibodyc N/A 3 (33.3) N/A 3 (17.6)
Number of ACR SLE criteria, median (range) N/A 3 (1–3) N/A 2 (1–3)
Abbreviations: ACR American College of Rheumatology, CLASI cutaneous lupus disease area and severity index, DLE discoid lupus erythematosus, N/A not
applicable, qRT-PCR quantitative real-time polymerase chain reaction, SLE systemic lupus erythematosus, SLEDAI systemic lupus erythematosus disease and
activity index
aDisease duration was not available for two patients with DLE
bNo patients with DLE had malar rash, arthritis, serositis, renal disorder, neurologic disorder, or immunological disorder
cPositive anti-nuclear antibody (ANA) test was determined by history of ANA titers of at least 1:160, as determined by indirect immunofluorescence, or positive
enzyme-linked immunosorbent assay
Chong et al. Arthritis Research & Therapy  (2015) 17:324 Page 3 of 10
anti-human CD3 antibody (eBioscience, Inc., San Diego,
CA, USA) was added for 1 hour, followed by PBS
washes. Slides were incubated with Alexa Fluor® 594-
conjugated goat anti-mouse antibodies (Life Technologies)
for 30 minutes and washed with PBS. Slides were cover-
slipped with Vectashield mounting medium and analyzed.
Images were acquired with an Olympus BX60 fluorescent
microscope (Olympus, Tokyo, Japan).
Statistical analysis
Based on 31,000 probed genes on the Illumina Human
HT-12v4 Expression BeadChip, a sample size of eight for
each study group was used and this had predicted power
to detect twofold gene expression difference with more
than 80 % power at a 5 % false-positive rate assuming a
standard deviation of 0.65 [23]. Microarray data were
quantum-normalized and background-subtracted by
using Bead Studio Software version 3.2.2 and analyzed
on GeneSpring GX (Agilent Technologies, Santa Clara,
CA, USA). To connect genes of interest with existing
biological pathways, Ingenuity Pathway Analysis
(Ingenuity System Inc., Redwood City, CA, USA) was
used to identify networks ordered by P values. Signifi-
cance Analysis of Microarrays (SAM) [24] helped
identify genes with statistically significant differences; q
values, defined as the lowest false discovery rate at which
genes were called significant by SAM analysis [25], were
less than 0.05. Gene set enrichment analysis was per-
formed to determine whether differentially expressed
genes were over-represented in referenced gene lists
[26], specifically those from macrophages incubated with
either interferon-gamma (IFN-γ) (M1 macrophages) or
IL-4 (M2 macrophages) [17]. Heat maps and clustering
analyses were performed by using Cluster and Treeview
software [27]. For qRT-PCR and immunohistochemistry
data, Mann-Whitney U test was used to compare the
two study groups.
Results
Transcriptomes of DLE lesional skin were enriched with
M1 macrophage-related genes
From a total of 21,628 genes, whose expression was ei-
ther “present” or “marginal” in at least 75 % of all sam-
ples, microarray analysis of DLE lesional skin (n = 9)
versus normal sun-exposed skin (n = 8) revealed 543 up-
regulated and 273 downregulated genes in DLE skin
(more than twofold, q < 0.05) (Fig. 1a and Additional
file 1: Table S2). Pathway analysis showed that the two
Fig. 1 Microarray analysis of DLE lesional and normal skin. a Heat map depicts the top 20 upregulated and downregulated genes in DLE lesional
skin (n = 9) versus normal skin (n = 8) (more than twofold, q < 0.05). Red and green represent high and low expression, respectively. b, c Venn
diagrams of differentially expressed genes in DLE versus normal skin, and macrophages treated with IFN-γ (M1) (b) or IL-4 (M2) (c) [17] demonstrated
that more upregulated genes in DLE skin were shared with those in IFN-γ-treated macrophages than IL-4 treated macrophages. DLE discoid lupus
erythematosus, IFN-γ interferon-gamma, IL-4 interleukin-4
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most significant signaling cascades included genes
involved in antigen presentation and cytotoxic T cell-
mediated apoptosis. Because IFN-γ was the top up-
stream regulator gene, these findings supported a
prominent role of cell-mediated immunity in DLE
pathogenesis. Specifically, we noted several upregulated
genes in DLE skin that may be expressed by different
cells associated with cell-mediated immunity (e.g., TH1
cells: CXCR3, signal transducer and activator of tran-
scription 1 (STAT1), and STAT4; CD8+ cells: gran-
zymes A, B, K, and perforin; and macrophages: CD68,
CD163, and CXCL10) (highlighted in Additional file 1:
Table S2).
We then focused on analyzing expression of
macrophage-related genes in DLE versus normal skin to
investigate macrophage polarization (M1 or M2) in DLE
skin. We first generated Venn diagrams to identify com-
mon genes in our lists of differentially expressed genes
in DLE and normal skin and previously published sets of
differentially expressed genes in macrophages before and
after treatment with IFN-γ (M1 macrophages) [17].
Eighty-one genes were commonly upregulated in both
gene sets, but none was mutually downregulated (Fig. 1b
and Additional file 1: Table S3). Differentially expressed
genes in DLE and normal skin and macrophages before
and after treatment with IL-4 (M2 macrophages) [17]
were also compared. Only two genes were enhanced in
both gene sets, and none was commonly decreased
(Fig. 1c and Additional file 1: Table S3). Gene set enrich-
ment analysis showed that upregulated genes in DLE
skin showed significant overlap with those in M1 macro-
phages (normalized enrichment score = 1.25, P = 0.02)
but not with those in M2 macrophages (Table 2). Thus,
both analyses showed that DLE skin was significantly
enriched with M1 macrophage-related genes.
qRT-PCR analysis confirms upregulation of multiple M1
macrophage-related genes in DLE skin
Several macrophage-related genes were selected for con-
firmatory qRT-PCR studies on DLE lesional (n = 17) and
normal sun-exposed (n = 12) skin. CD163 (2.83 fold
change (FC)) and CD68 (4.98 FC), which are both
markers used to identify macrophages, had significantly
higher levels in DLE skin than normal skin (P < 0.0001)
(Fig. 2a, b). Multiple M1 macrophage genes—e.g.,
CD127 (8.01 FC, P < 0.0001), TNF-α (1.92 FC, P =
0.047), CXCL10 (45.91 FC, P < 0.0001), STAT1 (11.96
FC, P < 0.0001), CCL5 (25.85 FC, P < 0.0001), CD86, and
Mx1—were also significantly upregulated in DLE skin
compared with normal skin (Fig. 2c–g and Additional
file 1: Table S4). IFN-γ and IL-12, two cytokines associ-
ated with M1 macrophages, were higher in DLE skin but
did not reach statistical significance (Additional file 1:
Table S4). With the exception of TGF-β (2.42 FC, P =
0.0002), which was significantly higher in DLE skin than
normal skin, multiple M2 macrophage genes—e.g.,
CD206 (0.72 FC, P = 0.32), CD209 (1.10 FC, P = 0.97),
arginase-1 (1.25 FC, P = 0.19), FOLR2, and IL-10—were
not differentially expressed in DLE and normal skin
(Fig. 2h–k and Additional file 1: Table S4). We also se-
lected type I interferon-inducible genes (e.g., Mx1,
ISG15, and Ly6E) and genes associated with TH1 cells
(e.g., CXCR3) and CD8+ T cells (e.g., CD8 and gran-
zyme B) for qRT-PCR analysis. These were significantly
elevated in DLE skin versus normal skin (P < 0.0001)
(Additional file 1: Table S4).
DLE lesional skin contained higher numbers of CD163+
macrophages than normal skin
Samples of DLE lesional skin (n = 5) and normal sun-
exposed skin (n = 6) were immunostained with CD163, a
scavenger receptor that is highly specific for macro-
phages in the skin [28] (Fig. 3a, b). DLE skin had signifi-
cantly higher concentrations of CD163+ cells at the
epidermal-dermal junction (median: 87.8 cells/mm2 versus
25.3 cells/mm2; P = 0.004) and perivascular areas (median:
128.9 cells/mm2 versus 48.6 cells/mm2; P = 0.03) than nor-
mal skin. DLE skin showed higher amounts of CD163+
cells in perifollicular areas compared with normal skin
(median: 50.0 cells/mm2 versus 10.0 cells/mm2), but this
difference did not reach statistical significance (P = 0.26)
(Fig. 3c–e).
A minority of CD163+ macrophages showed co-staining
with M1- and M2-related proteins in DLE skin
To determine whether CD163+ macrophages predomin-
antly expressed M1 or M2 macrophage-related proteins
or both, double immunostaining of CD163 and selected
Table 2 Gene set enrichment analysis of differentially expressed genes in DLE lesional and normal skin
Name Size ES NES P value FDR q value
IFN-γ-stimulated (M1) macrophages upregulated 113 0.92 1.25 0.02 0.02
IFN-γ stimulated (M1) macrophages downregulated 16 −0.55 −1.24 0.25 0.25
IL-4 stimulated (M2) macrophages upregulated 26 0.39 0.97 0.49 0.49
IL-4 stimulated (M2) macrophages downregulated 1 0.95 1.11 0.27 0.27
Abbreviations: DLE discoid lupus erythematosus, ES enrichment score, FDR false discovery rate, IFN-γ interferon-gamma, IL-4 interleukin-4, NES normalized
enrichment score
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M1 and M2 macrophage-related proteins (CXCL10,
CD127, TNF-α, TGF-β, and CD209) were performed in
DLE lesional (n = 6–8) and normal (n = 4 or 5) skin. DLE
and normal skin both showed a minority of CD163+
macrophages near the epidermal-dermal junction and
in the perivascular and periadnexal areas of the dermis
co-expressing CXCL10, CD127, TNF-α, TGF-β, and
CD209, and the greatest overlap was seen with CD209
(Fig. 4a–e). Because of this result, we postulated that
other inflammatory cells such as T cells could also con-
tribute to the upregulation of M1 macrophage-related
proteins in DLE lesional skin. Co-staining of a minority
of CD3+ T cells with CD127 was detected in the dermis
of DLE skin (Fig. 4f ).
Discussion
Transcriptome analysis of DLE lesional skin yielded
strong expression of a signature of M1 macrophage-
related genes. Inspection of selected M1 and M2
macrophage-related genes by qRT-PCR confirmed up-
regulation of multiple M1 macrophage-related genes in
DLE skin. Because M1 macrophages are activated by
IFN-γ that is produced by TH1 cells and promote TH1
responses through their antimicrobial activity [29], our
findings are consistent with earlier studies showing a
predominant TH1 bias in DLE skin [30]. Moreover, we
performed gene set enrichment analysis comparing pre-
viously published gene sets of TH1 and TH2 cells [31]
with DLE and normal skin transcriptome data and
Fig. 2 qRT-PCR analysis of selected genes in DLE lesional and normal skin. a–k RNA expression of general macrophage markers (CD163 and
CD68) (a, b), M1 macrophage-related markers (CD127, TNF-α, CXCL10, STAT1, and CCL5) (c–g), and M2 macrophage-related markers (TGF-β,
CD206, CD209, and arginase-1) (h–k) was compared in DLE lesional (n = 17) and normal (n = 12) skin via qRT-PCR. Multiple general and M1
macrophage-related markers were upregulated in DLE lesional skin. *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001. CCL chemokine (C-C motif)
ligand, CXCL chemokine (C-X-C motif) ligand, DLE discoid lupus erythematosus, qRT-PCR quantitative real-time polymerase chain reaction, STAT
signal transducer and activator of transcription, TGF-β transforming growth factor-beta, TNF-α tumor necrosis factor-alpha
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detected TH1-biased genes being highly expressed in
DLE skin (P = 0.01) (data not shown).
Given the limitations that whole skin biopsies rather
than isolated CD163+ skin macrophages were studied for
transcriptome analysis and that several upregulated
genes may be expressed by skin cells other than macro-
phages, we performed double immunofluorescence
staining to examine protein expression of CD163+ mac-
rophages in DLE skin. Some CD163+ macrophages
showed co-expression of various M1 (e.g., CD127,
CXCL10, and TNF-α) and M2 (CD209 and TGF-β)
macrophage-related proteins, and the greatest overlap
was seen with CD209. Although CD163 has been re-
ported by in vitro studies to be a M2-related macro-
phage marker [32, 33], immunostaining studies of
CD163+ macrophages in peripheral tissues of different
diseases have shown that they can express transcription
factors specific to either M1 or M2 macrophage signal-
ing pathways [34]. Specifically, studies on squamous cell
carcinoma of the skin have reported that CD163+ mac-
rophages can produce both M1 and M2 macrophage-
related proteins [35]. The presence of different macro-
phage subtypes may result from the ability of macro-
phages to change from one subtype to another in
response to various stimuli from the surrounding milieu.
For instance, IL-4 can guide the transformation of M1
macrophages into M2 macrophages, which promote
wound healing and angiogenesis [36]. Likewise, cyto-
kines such as IFN-γ produced by TH1 cells can alter the
polarization of M2 macrophages to M1 macrophages
that subsequently produce M1 macrophage-related cyto-
kines and enhance their co-stimulatory molecule expres-
sion [37]. Furthermore, exogenous signals such as
bacterial lipopolysaccharides can induce both M1 and
M2 macrophages to produce M1 macrophage-related cy-
tokines such as TNF-α and IL-1 [38].
The disease phase at the time of DLE skin biopsy may
have impacted the immunostaining characterization of
CD163+ macrophages. In the acute phase, DLE lesions
present clinically as erythematous scaly papules and pla-
ques and microscopically have interface dermatitis, scat-
tered apoptotic keratinocytes, mucin deposition, and
Fig. 3 CD163+ macrophages in normal skin and DLE lesional skin. a, b Immunohistochemical analysis of CD163 was performed in normal skin (n = 6)
(a) and DLE lesional skin (n = 5) (b). Total magnification: ×200. c–e CD163+ cell counts from representative high-powered fields of the epidermal-
dermal junction (c), perivascular areas (d), and perifollicular areas (e) of normal and DLE lesional skin showed significantly higher numbers of CD163+
macrophages in the epidermal-dermal junction and perivascular areas of DLE skin. *P≤ 0.05, **P≤ 0.01. DLE discoid lupus erythematosus
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perivascular and periadnexal inflammatory infiltrates
[39]. DLE lesions later evolve into hypopigmented
scarred plaques with peripheral hyperpigmentation in
the chronic phase, and their histopathology displays epi-
dermal atrophy, mild interface dermatitis, loss of hair
follicles, and dermal sclerosis [39]. M2 macrophages up-
regulate IL-10, which has anti-inflammatory properties.
TGF-β is a pro-fibrotic cytokine produced mainly by
M2c macrophages [40] and may contribute to the scar-
ring process that is seen in the latter stages of DLE. Fur-
thermore, TGF-β can have anti-inflammatory effects by
downregulating production of pro-inflammatory cyto-
kines such as TNF-α [41] and maintaining peripheral
tolerance by limiting the expansion of self-reactive T
cells [42]. Because many of these biopsied discoid lesions
had clinical features of both acute and chronic DLE, we
hypothesize that these lesions may be in a transitional
phase between acute and chronic DLE, and this could
explain the heterogeneity of macrophage subtypes. Fur-
ther projects that compare protein expression in acute
and chronic discoid skin lesions will be needed to test
whether macrophages strongly favor one polarization
over another in the two phases of DLE.
Macrophage bias in peripheral organs other than skin
has been investigated in murine models with lupus
nephritis. In lupus-prone MRL-lpr mice, transient ische-
mia/reperfusion injury resulted in early-onset lupus
nephritis with an accompanying increase in M1 macro-
phages compared with M2 macrophages [43]. However,
in other lupus murine models, heterogeneous popula-
tions of macrophages that did not show a distinct M1 or
M2 bias were described in chronic lupus nephritis kid-
neys [44]. Because human lupus nephritis and DLE
have similar features of acute inflammation and chronic
scarring, comparisons of macrophages in these two
end-organ diseases in lupus could be made to better
understand disease pathogenesis in lupus.
Our double immunofluorescence data also showed
that other cells, particularly T cells, contribute to en-
hanced levels of M1 macrophage-related proteins. A
Fig. 4 Double immunofluorescence staining for CD163+ macrophages and CD3+ T cells and selected macrophage markers in DLE lesional skin (n = 6–8).
a–e DLE lesional skin was stained with both antibodies to CD163 (red) and selected macrophage markers (green), including CXCL10 (a), CD127 (b), TNF-α
(c), TGF-β (d), and CD209 (e). Accompanying control slides are present on the upper right. Yellow arrowheads indicate example areas of overlap. A minority
of CD163+ macrophages co-stained with these proteins, and the most overlap was seen with CD209. (f) DLE lesional skin was also stained with antibodies
to CD3 (red) and CD127 (green). A subset of CD3+ T cells showed expression of CD127. Dotted line denotes epidermal-dermal junction. Total magnification:
×200. DLE discoid lupus erythematosus, TGF-β transforming growth factor-beta, TNF-α tumor necrosis factor-alpha
Chong et al. Arthritis Research & Therapy  (2015) 17:324 Page 8 of 10
minority of CD3+ T cells showed co-expression of
CD127, an M1 macrophage-related protein, in DLE
lesional skin. T cells have been described to express
other M1 macrophage-related proteins, including IFN-γ
[30]. Moreover, given that a TH1 cell bias has been ob-
served in DLE skin in our and other [30] data and that
TH1 cells can activate classically activated macrophages
through their secretion of IFN-γ, TH1 cells likely con-
tribute to the M1 macrophage gene signature in DLE
skin. Additionally, CD8+ T cells, which also produce
IFN-γ and activate macrophages, have been observed in
greater numbers in DLE skin [12, 45, 46]. Thus, the
cross-talking between TH1 cells, CD8
+ T cells, and mac-
rophages implies that cell-mediated immunity can play a
significant role in the pathogenesis of DLE. Further stud-
ies examining their interactions and impact on evolution
of DLE will be planned. As DLE skin is enriched with
multiple types of immune cells [13, 46], our qRT-PCR
data demonstrated that DLE skin upregulates cell surface
markers expressed by dendritic cells (CD86) and mono-
cytes (CD14), which can also express M1 macrophage-
related proteins (e.g., CXCL10 [47, 48] and ISG15 [49]).
Conclusions
Whereas transcriptome analysis suggested an M1
macrophage gene signature in DLE skin, immunohisto-
chemical studies of DLE skin uncovered a subset of
CD163+ macrophages expressing both M1 and M2
macrophage-related proteins. The diversity of macro-
phage subtypes may be due to their gene expression
plasticity and a mixture of acute and chronic phases in
the DLE biopsy skin specimens. Moreover, other im-
mune cells, such as CD3+ T cells, infiltrating into DLE
skin can contribute to the M1 macrophage gene signa-
ture in DLE skin. Further exploration into the multiple
immune cells expressing M1 macrophage-related pro-
teins and their interactions with each other will help fur-
ther explain the evolution of DLE.
Additional file
Additional file 1: Table S1. Forward and reverse primers for selected
genes. Table S2. Differentially expressed genes in DLE lesional (n = 9)
and normal (n = 8) skin from microarray analysis (more than twofold
change, q value < 0.05). Table S3. List of commonly differentially expressed
genes in DLE and normal skin, and IFN-γ treated (M1) and IL-4 treated (M2)
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(n = 17) and normal (n = 12) skin. DLE discoid lupus erythematosus, IFN-γ
interferon-gamma, qRT-PCR quantitative real-time polymerase chain reaction.
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